These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38260807)
1. Differential diagnosis of mild cognitive impairment of Alzheimer's disease by Simoa p-tau181 measurements with matching plasma and CSF. Wu L; Arvai S; Wang SJ; Liu AJ; Xu B Front Mol Neurosci; 2023; 16():1288930. PubMed ID: 38260807 [TBL] [Abstract][Full Text] [Related]
2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
3. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q; ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971 [TBL] [Abstract][Full Text] [Related]
4. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects. Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380 [TBL] [Abstract][Full Text] [Related]
5. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
6. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074 [TBL] [Abstract][Full Text] [Related]
8. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology. Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502 [TBL] [Abstract][Full Text] [Related]
9. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453 [TBL] [Abstract][Full Text] [Related]
10. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
11. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Janelidze S; Mattsson N; Palmqvist S; Smith R; Beach TG; Serrano GE; Chai X; Proctor NK; Eichenlaub U; Zetterberg H; Blennow K; Reiman EM; Stomrud E; Dage JL; Hansson O Nat Med; 2020 Mar; 26(3):379-386. PubMed ID: 32123385 [TBL] [Abstract][Full Text] [Related]
12. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum. Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667 [TBL] [Abstract][Full Text] [Related]
14. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease. Tieu MV; Choi SH; Le HTN; Cho S Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666 [TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment. Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC; J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656 [TBL] [Abstract][Full Text] [Related]
16. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H; Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600 [TBL] [Abstract][Full Text] [Related]
18. Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment. Laczó M; Martinkovic L; Lerch O; Wiener JM; Kalinova J; Matuskova V; Nedelska Z; Vyhnalek M; Hort J; Laczó J Front Aging Neurosci; 2022; 14():886778. PubMed ID: 35721017 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]